title: Distinguishing pseudoprogression from progression in high-grade gliomas: a brief review of current clinical practice and demonstration of the potential value of 18F-FDG PET.
abstract: We report a case in which 18F-FDG PET was able to discriminate pseudoprogression from progression observed on contrast-enhanced (CE) MRI (CE-MRI). A 56-year-old male patient with anaplastic oligodendroglioma demonstrated markedly increased tumor enhancement on CE-MRI 1 month after completing radiation therapy (RT), suggesting radiological progression. However, the patient was clinically improved and therefore received an early-therapy response assessment PET to assess for pseudoprogression. PET showed low tumor uptake indicating stable disease. Follow-up CE-MRI at 3 and 4 months post-RT confirmed stable disease. This case emphasizes the value of 18F-FDG PET when pseudoprogression is clinically suspected.
authors.affiliation: Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA.
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Oborski
authors.forename: Charles M
authors.initials: CM
authors.lastname: Laymon
authors.forename: Frank S
authors.initials: FS
authors.lastname: Lieberman
authors.forename: James M
authors.initials: JM
authors.lastname: Mountz
mesh_terms: D003937:Diagnosis, Differential; D018450:Disease Progression; D019788:Fluorodeoxyglucose F18; D005910:Glioma / Q000000981:diagnostic imaging* / Q000473:pathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D049268:Positron-Emission Tomography
chemical_list: D019788:Fluorodeoxyglucose F18